- Home
- MYNZ vs MBIO Comparison
MYNZ vs MBIO Comparison
Compare MYNZ & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | MBIO |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 4.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYNZ | MBIO |
|---|---|---|
| Price | $1.15 | $1.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 189.2K | 91.4K |
| Earning Date | 12-29-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $659,935.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.89 |
| 52 Week High | $8.20 | $21.95 |
Technical Indicators
Market Signals| Indicator | MYNZ | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 37.53 |
| Support Level | $1.09 | $1.05 |
| Resistance Level | $1.29 | $1.14 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 59.32 | 6.41 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.